Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 76.20
-1.35 (-1.74%)
Apr 29, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 6,667 | 5,724 | 5,395 | 3,215 | 1,682 | Upgrade
|
| Revenue Growth (YoY) | 16.46% | 6.11% | 67.82% | 91.07% | 186.34% | Upgrade
|
| Cost of Revenue | 1,682 | 1,540 | 1,476 | 844.62 | 522.75 | Upgrade
|
| Gross Profit | 4,985 | 4,185 | 3,919 | 2,370 | 1,160 | Upgrade
|
| Selling, General & Admin | 2,642 | 2,288 | 2,138 | 1,403 | 800.87 | Upgrade
|
| Research & Development | 1,515 | 1,035 | 1,119 | 1,395 | 1,024 | Upgrade
|
| Operating Expenses | 4,168 | 3,318 | 3,266 | 2,999 | 1,825 | Upgrade
|
| Operating Income | 817.12 | 866.5 | 652.95 | -628.53 | -665.25 | Upgrade
|
| Interest Expense | -102.49 | -122.89 | -110.54 | -105.67 | -84.82 | Upgrade
|
| Interest & Investment Income | 18.79 | 21.7 | 8.15 | 3.57 | 2.69 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 8.14 | -1.42 | 32.92 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 78.3 | 72.43 | 20.44 | 202.97 | -209.36 | Upgrade
|
| EBT Excluding Unusual Items | 811.72 | 845.88 | 569.58 | -494.73 | -956.74 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -199.15 | - | Upgrade
|
| Pretax Income | 811.72 | 845.88 | 569.58 | -693.89 | -956.74 | Upgrade
|
| Income Tax Expense | -15.32 | 25.41 | 23.56 | 1.37 | 27.31 | Upgrade
|
| Earnings From Continuing Operations | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 | Upgrade
|
| Net Income | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 | Upgrade
|
| Net Income to Common | 827.04 | 820.47 | 546.02 | -695.26 | -984.05 | Upgrade
|
| Net Income Growth | 0.80% | 50.26% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 543 | 543 | 543 | 542 | 539 | Upgrade
|
| Shares Outstanding (Diluted) | 546 | 543 | 543 | 542 | 539 | Upgrade
|
| Shares Change (YoY) | 0.45% | 0.02% | 0.25% | 0.59% | 1.75% | Upgrade
|
| EPS (Basic) | 1.52 | 1.51 | 1.01 | -1.28 | -1.83 | Upgrade
|
| EPS (Diluted) | 1.51 | 1.51 | 1.00 | -1.28 | -1.83 | Upgrade
|
| EPS Growth | 0.03% | 50.96% | - | - | - | Upgrade
|
| Free Cash Flow | - | 1,078 | 574.25 | 396.65 | -370.04 | Upgrade
|
| Free Cash Flow Per Share | - | 1.98 | 1.06 | 0.73 | -0.69 | Upgrade
|
| Gross Margin | 74.77% | 73.10% | 72.64% | 73.73% | 68.93% | Upgrade
|
| Operating Margin | 12.26% | 15.14% | 12.10% | -19.55% | -39.54% | Upgrade
|
| Profit Margin | 12.41% | 14.33% | 10.12% | -21.63% | -58.49% | Upgrade
|
| Free Cash Flow Margin | - | 18.83% | 10.64% | 12.34% | -21.99% | Upgrade
|
| EBITDA | 1,112 | 1,162 | 932.58 | -419.93 | -518.3 | Upgrade
|
| EBITDA Margin | 16.69% | 20.29% | 17.29% | -13.06% | -30.80% | Upgrade
|
| D&A For EBITDA | 295.29 | 295.29 | 279.63 | 208.6 | 146.95 | Upgrade
|
| EBIT | 817.12 | 866.5 | 652.95 | -628.53 | -665.25 | Upgrade
|
| EBIT Margin | 12.26% | 15.14% | 12.10% | -19.55% | -39.54% | Upgrade
|
| Effective Tax Rate | - | 3.00% | 4.14% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.